Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Whitehawk Therapeutics (WHWK) EBIT Margin (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed EBIT Margin for 7 consecutive years, with 212.99% as the latest value for Q1 2025.

  • Quarterly EBIT Margin rose 15152.0% to 212.99% in Q1 2025 from the year-ago period, while the trailing twelve-month figure was 60.53% through Dec 2025, up 19909.0% year-over-year, with the annual reading at 60.53% for FY2025, 19909.0% up from the prior year.
  • EBIT Margin for Q1 2025 was 212.99% at Whitehawk Therapeutics, up from 261.76% in the prior quarter.
  • The five-year high for EBIT Margin was 113.89% in Q4 2021, with the low at 3405.83% in Q1 2021.
  • Average EBIT Margin over 5 years is 517.45%, with a median of 296.0% recorded in 2022.
  • Peak annual rise in EBIT Margin hit 280705bps in 2022, while the deepest fall reached -18211bps in 2022.
  • Over 5 years, EBIT Margin stood at 113.89% in 2021, then tumbled by -160bps to 296.0% in 2022, then increased by 5bps to 280.02% in 2023, then rose by 7bps to 261.76% in 2024, then increased by 19bps to 212.99% in 2025.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 212.99%, 261.76%, and 185.98% for Q1 2025, Q4 2024, and Q3 2024 respectively.